Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.62 |
| ▸ | CES1 | P23141 | 3/20 | 0.62 |
| ▸ | PARP1 | P09874 | 7/20 | 0.60 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7077548 | 0.94 | PARP1 (0.60) | CES2CES1PARP1HCAR1CYP3A4 | |
| Thiourea SCHEMBL28876257 | 0.93 | CES2 (0.54) | CES2CES1PARP1HCAR1CYP3A4 | |
| SCHEMBL27940624 | 0.85 | HCAR1 (0.59) | CES2CES1PARP1HCAR1CYP3A4 | |
| SCHEMBL31196365 | 0.85 | HCAR1 (0.65) | CES2CES1PARP1HCAR1CYP3A4 | |
| SCHEMBL3090976 | 0.85 | PARP1 (0.52) | CES2CES1PARP1HCAR1CYP3A4 | |
| SCHEMBL21516794 | 0.85 | PARP1 (0.52) | CES2CES1PARP1HCAR1CYP3A4 | |
| SCHEMBL16953124 | 0.84 | PARP1 (0.50) | CES2CES1PARP1HCAR1CYP3A4 | |
| SCHEMBL2468003 | 0.84 | PARP1 (0.50) | CES2CES1PARP1HCAR1CYP3A4 | |
| SCHEMBL9631667 | 0.84 | PARP1 (0.50) | CES2CES1PARP1HCAR1CYP3A4 | |
| SCHEMBL12607365 | 0.84 | PARP1 (0.50) | CES2CES1PARP1HCAR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 351 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3994134-B9 | PROCESS FOR MANUFACTURING (S)-3-HYDROXY-1-(1H-INDOL-5-YL)-2-OXO-PYRROLIDINE-3-CARBOXYLIC ACID 3,5-DIFLUORO-BENZYLAMIDE | MERCK PATENT GMBH (DE) | 2024-06-26 | — | — | EP | claimed |
| EP-4034257-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-05-22 | — | — | EP | claimed |
| EP-3660003-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-01-24 | — | — | EP | claimed |
| EP-3994134-B1 | PROCESS FOR MANUFACTURING (S)-3-HYDROXY-1-(1H-INDOL-5-YL)-2-OXO-PYRROLIDINE-3-CARBOXYLIC ACID 3,5-DIFLUORO-BENZYLAMIDE | MERCK PATENT GMBH (DE) | 2024-01-24 | — | — | EP | claimed |
| CN-106715415-B | 3-amino-1, 5,6, 7-tetrahydro-4H-indol-4-ones | 拜耳制药股份公司 | 2019-06-14 | — | — | CN | claimed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| CN-108129340-A | A kind of preparation method of benzamide ortho position allyated products and its purification method | 温州大学 | 2018-06-08 | — | — | CN | claimed |
| CN-106715415-A | 3-amino-1, 5,6, 7-tetrahydro-4H-indol-4-ones | 拜耳制药股份公司 | 2017-05-24 | — | — | CN | claimed |
| EP-2906559-B1 | AZAINDOLINES | HOFFMANN LA ROCHE (CH) | 2017-02-08 | — | — | EP | claimed |
| US-9309248-B2 | Azaindolines | HOFFMANN-LA ROCHE INC. (US) | 2016-04-12 | — | — | US | claimed |
| US-20040242604-A1 | Substituted heterocycles for the treatment of abnormal cell growth | PFIZER INC | 2004-12-02 | — | — | US | claimed |
| US-20040224992-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-11-11 | — | — | US | claimed |
| WO-2004075864-A2 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-09-10 | — | — | WO | claimed |
| EP-1149094-B1 | 4-(AMINOALKOXY)BENZOFURANS AS N-MYRISTOYLTRANSFERASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2004-04-21 | — | — | EP | claimed |
| WO-2004005278-A1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LIMITED (GB) | 2004-01-15 | — | — | WO | claimed |
| US-6376491-B1 | BENZOFURAN DERIVATIVES FOR TREATMENT OR PREVENTION OF MYCOSIS IN MAMMALS | BASILEA PHARMACEUTICA AG (CH) | 2002-04-23 | — | — | US | claimed |
| WO-2002028353-A2 | PHOSPHATE TRANSPORT INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-04-11 | — | — | WO | claimed |
| EP-1149094-A2 | 4-(AMINOALKOXY)BENZOFURANS AS N-MYRISTOYLTRANSFERASE INHIBITORS | Basilea Pharmaceutica AG (CH) | 2001-10-31 | — | — | EP | claimed |
| WO-2000037464-A2 | 4-(AMINOALKOXY)BENZOFURANS AS N-MYRISTOYLTRANSFERASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2000-06-29 | — | — | WO | claimed |
| WO-1993014062-A1 | ANTHELMINTIC β-KETOAMIDES | THE UPJOHN COMPANY (US) | 1993-07-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242604-A1 | Substituted heterocycles for the treatment of abnormal cell growth | CCNA1, CCNT1, CCNY | CES2 2417/4885CES1 345/4885PARP1 1077/4885 |
| US-20040224992-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | CES2 3702/4885CES1 803/4885PARP1 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.